

MEDICAL POLICY



| | |
|---|--|
| SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS | EFFECTIVE DATE: 03/21/01 REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18 |
| POLICY NUMBER: 2.01.31 CATEGORY: Technology Assessment | PAGE: 1 OF: 7 |
| <ul style="list-style-type: none">• <i>If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</i>• <i>If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.</i>• <i>If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</i> | |

POLICY STATEMENT:

- I. Based upon our criteria and the assessment of peer-reviewed literature, extracorporeal shock wave therapy (ESWT) for the treatment of musculoskeletal conditions, including, but not limited to, chronic plantar fasciitis, tendonitis of the shoulder and elbow, and non-union of fractures, has not been medically proven to be effective and therefore is considered **investigational**.
- II. Based upon our criteria and the assessment of peer-reviewed literature, extracorporeal shock wave therapy (ESWT) as a treatment for wound healing has not been medically proven to be effective and therefore is considered **investigational**.

POLICY GUIDELINES:

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

Extracorporeal shock wave therapy (ESWT) is proposed as a non-surgical treatment option for musculoskeletal conditions, including chronic plantar fasciitis and tendonitis of the shoulder and elbow, as well as for non-union of fractures. The mechanism by which ESWT achieves a therapeutic intervention in orthopedic conditions is not completely understood, but there are several hypotheses. ESWT may disrupt fibrous tissue allowing for the subsequent promotion of revascularization and healing of tissue. Also, it is believed that the direct and indirect effects of the shock waves may damage cell membranes so that nociceptors cannot build up a potential to transmit pain signals. Chronic conditions such as tendinitis can be associated with a substantial degree of scarring and calcium deposition. Calcific deposits may restrict motion and encroach on nerves and blood vessels, causing pain and dysfunction. It is thought that the shock waves will break up these deposits, loosen structures, promote resorption of calcium, thereby decreasing pain and improving function.

Both high-dose and low-dose focused ESWT have been utilized. A high-dose protocol consists of a single treatment of high-energy shock waves (1300mJ/mm²). This painful procedure requires anesthesia. A low-dose protocol consists of multiple treatments, spaced 1 week to 1 month apart, in which a lower dose of shock waves is applied. This protocol does not require anesthesia.

Another type of ESWT is under investigation. Radial ESWT is generated ballistically by accelerating a bullet to hit an applicator, which transforms the kinetic energy into radially expanding shock waves. Other types of ESWT produce focused shock waves that show deeper tissue penetration with significantly higher energies concentrated to a small focus. Radial ESWT is described as an alternative to focused ESWT and is said to address larger treatment areas, thus providing potential advantages in superficial applications like tendinopathies.

ESWT is being proposed as a new approach to soft tissue wound healing. It is being studied as a treatment for delayed or chronic, non-healing wounds and also as a therapy to accelerate tissue repair in wounds such as diabetic ulcers and burns. Although the precise mechanism by which ESWT could provide a therapeutic effect is not known, it is thought

| | |
|--|---|
| <p>SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS</p> <p>POLICY NUMBER: 2.01.31</p> <p>CATEGORY: Technology Assessment</p> | <p>EFFECTIVE DATE: 03/21/01</p> <p>REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18</p> <p>PAGE: 2 OF: 7</p> |
|--|---|

that ESWT may decrease inflammation and induce neovascularization, allowing for improved perfusion and accelerated epithelialization.

RATIONALE:

The OssaTron® device (Health Tronics) was approved by the FDA in July 2000 for chronic proximal plantar fasciitis and is also approved for use in the treatment of lateral epicondylitis. Dornier MedTech, Inc. received FDA approval for its Premarket Application for Epo Ultra® extracorporeal shock wave therapy device on January 15, 2002 for the treatment of plantar fasciitis. Siemens’ SONOCUR® Basic System was approved in July 2002 for treatment of epicondylitis (tennis elbow). Orthometrix’s Orbasone™ Pain relief System and Medispec’s Orthospec™, received FDA premarket approval in 2005; both are approved to treat plantar fasciitis. The FDA-labeled indication for the OssaTron® and Epos™ Ultra device specifically describes a high-dose protocol, while the labeled indication for the SONOCUR® device describes a low-dose protocol. Radial ESWT (rESWT) received pre-market approval (PMA) in May 2007. The FDA-approved device is the Doloclast (spelled Dolorclast in the PMA summary) from EMS Electro Medical Systems, Nyon, Switzerland.

There is insufficient data published in the peer-reviewed literature to draw conclusions about the effectiveness of either focused or radial ESWT for treatment of musculoskeletal conditions. Outcomes of trials on clinically relevant measures are inconsistent and interpretation complicated by variations in treatment protocols. Published evidence for the use of ESWT to promote healing of fracture non-union consists of reports of case series only, and it cannot be concluded from such studies that ESWT results in acceleration of union.

Likewise, the available evidence in the medical literature evaluating the safety and efficacy of ESWT for wound healing is insufficient to support its use for this indication at the present time.

CODES: Number Description

Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

| | | |
|--------------------|-------------|--|
| <u>CPT:</u> | 0101T (E/I) | Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy |
| | 0102T (E/I) | Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle |
| | 0299T (E/I) | Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound |
| | 0300T (E/I) | Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound |
| | 28890 (E/I) | Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia |

Copyright © 2018 American Medical Association, Chicago, IL

HCPCS: No specific code(s)

ICD10: M72.2 Plantar fascial fibromatosis

| | |
|--|---|
| <p>SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS</p> <p>POLICY NUMBER: 2.01.31</p> <p>CATEGORY: Technology Assessment</p> | <p>EFFECTIVE DATE: 03/21/01</p> <p>REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18</p> <p>PAGE: 3 OF: 7</p> |
|--|---|

M75.30-M75.32 Calcific tendinitis of shoulder (code range)

M77.10-M77.12 Lateral epicondylitis, elbow (code range)

M77.30-M77.32 Calcaneal spur, foot (code range)

Multiple ICD10 diagnosis codes for open wounds and burns

REFERENCES:

*Alves EM, et al. The use of extracorporeal shock waves in the treatment of osteonecrosis of the femoral head: a systematic review. Clin Rheumatol 2009 Nov;28(11):1247-1251.

Aqil A, et al. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: a meta-analysis of RCTs. Clin Orthop Relat Res 2013 Nov;471(11):3645-52.

Bannuru RR, et al. High-energy extracorporeal shock-wave therapy for treating chronic calcific tendinitis of the shoulder: a systematic review. Ann Intern Med 2014 Apr 15;160(8):542-9.

Beyazel MS, et al. Comparison of the effectiveness of local corticosteroid injection and extracorporeal shock wave therapy in patients with lateral epicondylitis. J Phys Ther Sci 2015 Dec;27(12):3755-8.

BlueCross BlueShield Association. Extracorporeal shock wave treatment for plantar fasciitis and other musculoskeletal conditions. Medical Policy Reference Manual Policy #2.01.40. 2017 June 08.

*BlueCross BlueShield Technology Evaluation Center. Extracorporeal Shock Wave Therapy (ESWT) for musculoskeletal conditions. 2003 Aug;18(5):1-42.

*Buchbinder R, et al. Systematic review of the efficacy and safety of shock wave therapy for lateral elbow pain. J Rheum 2006;33(7):1351-63.

Butterworth PA, et al. The effectiveness of extracorporeal shock wave therapy for the treatment of lower limb ulceration: a systematic review. J Foot Ankle Res 2015 Feb 5;8:3.

*Cacchio A, et al. Extracorporeal shock-wave therapy compared with surgery for hypertrophic long-bone unions. J Bone Joint Surg Am 2009 Nov;91(11):2589-97.

Carulli C, et al. Effectiveness of extracorporeal shockwave therapy in three major tendon diseases. J Orthop Traumatol 2016 March;17(1):15-20.

*Chen JM, et al. Functional outcomes of bilateral hip necrosis: total hip arthroplasty versus extracorporeal shockwave. Arch Orthop Trauma Surg 2009 Jun;129(6):837-41.

*Chuckpaiwong B, et al. Extracorporeal shock wave for chronic proximal plantar fasciitis: 225 patients with results and outcome predictors. J Foot Ankle Surg 2009 Mar-Apr;48(2):148-55.

Dingemans R, et al. Evidence for the effectiveness of electrophysical modalities for treatment of medial and lateral epicondylitis: a systematic review. Br J Sports Med 2014 Jun;48(12):957-65.

Dizon JN, et al. Effectiveness of extracorporeal shock wave therapy in chronic plantar fasciitis: a meta-analysis. Am J Phys Med Rehabil 2013 Jul;92(7):606-20.

*Furia JP. High-energy extracorporeal shock wave therapy as a treatment for insertional Achilles tendinopathy. A J Sports Med 2006;34(5):733-40.

*Furia JP, et al. Low-energy extracorporeal shock wave therapy as treatment for greater trochanteric pain syndrome. Am J Sports Med 2009 Sep;37(9):1806-13.

| | |
|--|---|
| <p>SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS</p> <p>POLICY NUMBER: 2.01.31</p> <p>CATEGORY: Technology Assessment</p> | <p>EFFECTIVE DATE: 03/21/01</p> <p>REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18</p> <p>PAGE: 4 OF: 7</p> |
|--|---|

Galasso O, et al. Short-term outcomes of extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomized, placebo- controlled trial. BMC Musculoskelet Disord 2012 Jun 6;13:86.

*Gerdesmayer L, et al. Radial extracorporeal shock wave therapy is a safe and effective in the treatment of chronic recalcitrant plantar fasciitis: results of a confirmatory randomized placebo-controlled multicenter study. Am J Sports Med 2008 Nov;36(11):2100-9.

*Gollwitzer H, et al. Extracorporeal shock wave therapy for chronic painful heel syndrome: a prospective, double blind, randomized trial assessing the efficacy of a new electromagnetic shock wave device. J Foot Ankle Surg 2007 Sep-Oct;46(5):348-57.

Gollwitzer H, et al. Clinically relevant effectiveness of focused extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: a randomized, controlled multicenter study. J Bone Joint Surg Am 2015 May 6;97(9):701-8.

*Greve JM, et al. Comparison of radial shockwaves and conventional physiotherapy for treating plantar fasciitis. Clinics 2009;64(2):97-103.

*Haake M, et al. Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. Brit Med J 2003 Jul;327(7406):75-7.

*Hearnden A, et al. Extracorporeal shock wave therapy in chronic calcific tendinitis of the shoulder- is it effective? Acta Orthop Belg 2009 Feb;75(1):25-31.

*Ho C. Extracorporeal shock wave treatment for chronic lateral epicondylitis (tennis elbow). Issues Emerg Health Technol 2007 Jan;(96 part 2):1-4.

Hsiao MY, et al. Comparative effectiveness of autologous blood-derived products, shock-wave therapy and corticosteroids for treatment of plantar fasciitis: a network meta-analysis. Rheumatology 2015 Sep;54(9):1735-43.

*Huisstede BM, et al. Evidence for effectiveness of extracorporeal shockwave therapy (ESWT) to treat calcific and non-calcific rotator cuff tendinosis- a systematic review. Man Ther 2011 Oct;16(5):419-33.

*Institute for Clinical Systems Improvement. Technology assessment report: extracorporeal shock wave therapy for plantar fasciitis. TA #86. 2004 Nov.

Ioppolo F, et al. Extracorporeal shock-wave therapy for supraspinatus calcifying tendinitis: a randomized clinical trial comparing two different energy levels. Phys Ther 2012 Nov;92(11):1376-85.

Ioppolo F, et al. Clinical improvement and resorption of calcifications in calcific tendinitis of the shoulder after shock wave therapy at 6 months' follow-up: a systematic review and meta-analysis. Arch Phys Med Rehabil 2013 Sep;94(4):1699-706.

Jung YJ, et al. Outcomes of ultrasound-guided extracorporeal shock wave therapy for painful stump neuroma. Ann Rehabil Med 2014 Aug;38(4):523-33.

Kim YS, et al. Which method is more effective in treatment of calcific tendinitis in the shoulder? Prospective randomized comparison between ultrasound-guided needling and extracorporeal shock wave therapy. J Shoulder Elbow Surg 2014 Nov;23(11):1640-6.

*Kudo P, et al. Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracorporeal shockwave therapy (ESWT) device; a north American confirmatory study. J Ortho Res 2006 Feb;24(2):115-23.

Lee S, et al. Effects of extracorporeal shockwave therapy on patients with chronic low back pain and their dynamic balance ability. J Phys Ther Sci 2014 Jan;26(1):7-10.

| | |
|--|---|
| <p>SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS</p> <p>POLICY NUMBER: 2.01.31</p> <p>CATEGORY: Technology Assessment</p> | <p>EFFECTIVE DATE: 03/21/01</p> <p>REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18</p> <p>PAGE: 5 OF: 7</p> |
|--|---|

Lee JY, et al. Effects of extracorporeal shock wave therapy on spasticity in patients after brain injury: A meta-analysis. J Phys Ther Sci 2014 Oct;26(10):1641-7.

Lizis P. Analgesic effect of extracorporeal shock wave therapy versus ultrasound therapy in chronic tennis elbow. J Phys Ther Sci 2015 Aug;27(8):2563-7.

Louwerens JK, et al. The effectiveness of high-energy extracorporeal shockwave therapy versus ultrasound-guided needling versus arthroscopic surgery in the management of chronic calcific rotator cuff tendinopathy: a systematic review. Arthroscopy 2016 Jan;32(1):165-175.

*Malay DS, et al. Extracorporeal shockwave therapy versus placebo for the treatment of chronic proximal plantar fasciitis: results of a randomized , placebo-controlled, double-blinded, multicenter intervention trial. J Foot Ankle Surg 2006 Jul/Aug;45(4):196-210.

Mandani-Kivi M, et al. Treatment outcomes of corticosteroid injection and extracorporeal shock wave therapy as two primary therapeutic methods for acute plantar fasciitis: a prospective randomized clinical trial. J Foot Ankle Surg 2015 Nov-Dec;54(6):1047-52.

Mani-Babu S, et al. The effectiveness of extracorporeal shock wave therapy in lower limb tendinopathy: A systematic review. Am J Sports Med 2015 Mar;43(3):752-61.

Moghtaderi A, et al. Extracorporeal shock wave therapy of gastroc-soleus trigger points in patients with plantar fasciitis: A randomized, placebo-controlled trial. Adv Biomed Res 2014 Mar 25;3:99.

*National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory Achilles tendinopathy. 2009 Aug [<http://www.nice.org.uk/guidance/index.jsp>] accessed 5/21/18.

*National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory plantar fasciitis. 2009 Aug [<http://www.nice.org.uk/guidance/index.jsp>] accessed 5/21/18.

*National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory tennis elbow. 2009 Aug [<http://www.nice.org.uk/guidance/index.jsp>] accessed 5/21/18.

National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory greater trochanter pain syndrome. IPG 376. Jan 2011 [<http://www.nice.org.uk/guidance/IPG376/Guidance/pdf>] accessed 5/21/18.

Notarnicola A, et al. Effects of extracorporeal shock wave therapy on functional and strength recovery of handgrip in patients affected by epicondylitis. Ultrasound Med Biol 2014 Dec;40(12):2830-40.

Notarnicola A, et al. Prognostic factors of extracorporeal shock wave therapy for tendinopathies. Musculoskelet Surg 2016 Apr;100(1):53-61.

*Othman AM, et al. Endoscopic plantar fasciotomy versus extracorporeal shock wave therapy for treatment of chronic plantar fasciitis. Arch Orthop Trauma Surg 2010 Nov;130(11):1343-7.

*Ottomann C, et al. prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. J Am Coll Surg 2010 Sep;211(3):361-7.

*Ozturan KE, et al. Autologous blood and corticosteroid injection and extracorporeal shock wave therapy in the treatment of lateral epicondylitis. Orthopedics 2010 Feb 1;33(2):84-91.

*Palmier A, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shockwave therapy for the treatment of Peyronie's disease. Eur Urol 2009 Aug;56(2):363-9.

Park JW, et al. Long-term outcome of low-energy extracorporeal shock wave therapy for plantar fasciitis: comparative analysis according to ultrasonographic findings. Ann Rehabil Med 2014 Aug;38(4):534-40.

| | |
|--|---|
| <p>SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS</p> <p>POLICY NUMBER: 2.01.31</p> <p>CATEGORY: Technology Assessment</p> | <p>EFFECTIVE DATE: 03/21/01</p> <p>REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18</p> <p>PAGE: 6 OF: 7</p> |
|--|---|

Park JW, et al. Comparison of therapeutic effect of extracorporeal shock wave in calcific versus noncalcific epicondylopathy. Ann Rehabil Med 2016 Apr;40(2):294-300.

*Pleiner J, et al. Extracorporeal shockwave treatment is effective in calcific tendonitis of the shoulder. A randomized controlled trial. Wien Klin Wochenschr 2004;116(15-16):536-41.

*Rasmussen S, et al. Shockwave therapy for chronic Achilles tendinopathy: a double-blind, randomized clinical trial of efficacy. Acta Orthop 2008 Apr;79(2):249-56.

Roca B, et al. Comparison of extracorporeal shock wave therapy with botulinum toxin type A in the treatment of plantar fasciitis. Disabil Rehabil 2016 Mar 1:108.

Saggini R, et al. Clinical application of shock wave therapy in musculoskeletal disorders: part II related to myofascial and nerve apparatus. J Biol Regul Homost Agents 2015 Oct-Dec;29(4):771-85.

Santamato A, et al. Extracorporeal shock wave therapy for the treatment of poststroke plantar-flexor muscles spasticity: a prospective open-label study. Top Stroke Rehabil 2014;21 Suppl 1:S17-24.

*Saxena A, et al. Extra-corporeal pulse-activated therapy (“EPAT” sound wave) for Achilles tendinopathy: a prospective study. J Foot Ankle Surg 2011 May-Jun;50(3):315-9.

Scheuer R, et al. Approaches to optimize focused extracorporeal shockwave therapy (ESWT) based on an observational study of 363 feet with recalcitrant plantar fasciitis. Int J Surg 2016 Mar;27:1-7.

*Schofer MD, et al. High-versus low-energy extracorporeal shock wave therapy of rotator cuff tendinopathy: a prospective, randomized, controlled study. Acta Orthop Belg 2009 Aug;75(4):452-8.

Schmitz C, et al. Treatment of chronic plantar fasciopathy with extracorporeal shock waves (review). J Orthop Surg Res 2013 Sep 3;8:31.

Smith J, et al. Comparing PRP injections with ESWT for athletes with chronic patellar tendinopathy. Clin J Sport Med 2014 Jan;24(1):88-9.

*Speed CA, et al. Extracorporeal shock wave therapy for plantar fasciitis - A double blind randomised controlled trial. J Orthop Res 2003 Sep;21(5):937-40.

*Staples MP, et al. A randomized controlled trial of extracorporeal shock wave therapy for lateral epicondylitis (tennis elbow). J Rheumatol 2008 Oct;35(10):2038-46.

Taylor J, et al. Extracorporeal shockwave therapy (ESWT) for refractory Achilles tendinopathy: a prospective audit with 2-year follow up. Foot 2016 March;26:23-29.

*Tornese D, et al. Comparison of two extracorporeal shock wave therapy techniques for the treatment of painful subcalcaneal spur. A randomized controlled study. Clin Rehabil 2008 Sep;22(9):780-7.

Verstraelen FU, et al. High-energy versus low-energy extracorporeal shock wave therapy for calcifying tendinitis of the shoulder. Which is superior? A meta-analysis. Clin Orthop Relat Res Sep 2014;472(9):2816-25.

*Vidal X, et al. Radial extracorporeal shock wave therapy (rESWT) in the treatment of spasticity in cerebral palsy: a randomized, placebo-controlled clinical trial. NeuroRehabilitation 2011;29(4):413-9.

Vulpiani MC, et al. Extracorporeal shock wave therapy vs cryoultrasound therapy in the treatment of chronic lateral epicondylitis. One year follow up study. Muscles Ligaments Tendons J 2015 Oct 20;5(3):167-74.

Yin MC, et al. Is extracorporeal shock wave therapy clinical efficacy for relief of chronic, recalcitrant plantar fasciitis: A systematic review and meta-analysis of randomized placebo or active-treatment controlled trials. Arch Phys Med Rehabil 2014 Aug;95(8):1585-93.

| | |
|--|---|
| <p>SUBJECT: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS</p> <p>POLICY NUMBER: 2.01.31</p> <p>CATEGORY: Technology Assessment</p> | <p>EFFECTIVE DATE: 03/21/01</p> <p>REVISED DATE: 02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18</p> <p>PAGE: 7 OF: 7</p> |
|--|---|

Zhang Q, et al. Extracorporeal shockwave therapy in osteonecrosis of femoral head: a systematic review of now available clinical evidences. Medicine 2017 Jan;96(4):e5897.

*Zimmermann R, et al. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomized, double-blind, placebo-controlled study. Eur Urol 2009 Sep;56(3):418-24.

* key article

KEY WORDS:

Lithotripsy, Orthotripsy, Ossatron

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based on our review, extracorporeal shock wave therapy for musculoskeletal conditions is not addressed in National or Regional Medicare coverage determinations or policies. However, there is a local coverage determination that addresses category III codes located at: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33392&ver=86&CtrctrSelected=298*1&Ctrctr=298&s=41&DocType=All&LCntrctr=138*1&kq=1484874194&ua=highwire&displayPDFNote=Y&bc=AggAAAQBAAAA&